Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

Accumulation of protease mutations among patients failing second-line antiretroviral therapy and response to salvage therapy in Nigeria.

Rawizza HE, Chaplin B, Meloni ST, Darin KM, Olaitan O, Scarsi KK, Onwuamah CK, Audu RA, Chebu PR, Imade GE, Okonkwo P, Kanki PJ.

PLoS One. 2013 Sep 17;8(9):e73582. doi: 10.1371/journal.pone.0073582. eCollection 2013.

2.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
3.

Impact of genotypic resistance testing on selection of salvage regimen in clinical practice.

Haupts S, Ledergerber B, Böni J, Schüpbach J, Kronenberg A, Opravil M, Flepp M, Speck RF, Grube C, Rentsch K, Weber R, Günthard HF; Swiss HIV Cohort Study.

Antivir Ther. 2003 Oct;8(5):443-54.

PMID:
14640392
4.

Accumulation of drug resistance and loss of therapeutic options precede commonly used criteria for treatment failure in HIV-1 subtype-C-infected patients.

Barth RE, Aitken SC, Tempelman H, Geelen SP, van Bussel EM, Hoepelman AI, Schuurman R, Wensing AM.

Antivir Ther. 2012;17(2):377-86. doi: 10.3851/IMP2010. Epub 2011 Dec 2.

PMID:
22297391
5.

Impact of drug resistance mutations on virologic response to salvage therapy. Swiss HIV Cohort Study.

Lorenzi P, Opravil M, Hirschel B, Chave JP, Furrer HJ, Sax H, Perneger TV, Perrin L, Kaiser L, Yerly S.

AIDS. 1999 Feb 4;13(2):F17-21.

PMID:
10202819
6.

Mutations at codons 54 and 82 of HIV protease predict virological response of HIV-infected children on salvage lopinavir/ritonavir therapy.

Luis Jiménez J, Resino S, Martinez-Colom A, Bellón JM, Angeles Muñoz-Fernández M; Spanish Group of Paediatric HIV Infection.

J Antimicrob Chemother. 2005 Dec;56(6):1081-6. Epub 2005 Sep 29.

7.

Tenofovir-based regimens associated with less drug resistance in HIV-1-infected Nigerians failing first-line antiretroviral therapy.

Etiebet MA, Shepherd J, Nowak RG, Charurat M, Chang H, Ajayi S, Elegba O, Ndembi N, Abimiku A, Carr JK, Eyzaguirre LM, Blattner WA.

AIDS. 2013 Feb 20;27(4):553-61. doi: 10.1097/QAD.0b013e32835b0f59.

PMID:
23079810
8.

HIV-1 genotypic resistance profile of patients failing antiretroviral therapy in Paraná, Brazil.

Toledo PV, Carvalho DS, Romagnoli L, Marcinko G, Cunha CA, Souza MN, Brindeiro R, Queiroz-Telles Fd.

Braz J Infect Dis. 2010 Jul-Aug;14(4):360-71.

9.

Efficient monitoring of HIV-1 vertically infected children in Kenya on first-line antiretroviral therapy.

Lihana RW, Lwembe RM, Bi X, Ochieng W, Panikulam A, Palakudy T, Musoke R, Owens M, Ishizaki A, Okoth FA, Songok EM, Ichimura H.

J Clin Virol. 2011 Oct;52(2):123-8. doi: 10.1016/j.jcv.2011.06.014. Epub 2011 Jul 27.

PMID:
21798798
10.

Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor.

Barber TJ, Harrison L, Asboe D, Williams I, Kirk S, Gilson R, Bansi L, Pillay D, Dunn D; UK HIV Drug Resistance Database and UK Collaborative HIV Cohort (UK CHIC) Study Steering Committees.

J Antimicrob Chemother. 2012 Apr;67(4):995-1000. doi: 10.1093/jac/dkr569. Epub 2012 Jan 17.

11.
12.

Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the Western Cape, South Africa.

van Zyl GU, van der Merwe L, Claassen M, Zeier M, Preiser W.

J Med Virol. 2011 Oct;83(10):1764-9. doi: 10.1002/jmv.22189.

PMID:
21837793
13.

Treatment limitations imposed by antiretroviral drug resistance mutations: implication for choices of first line regimens in resource-limited settings.

Mtambo A, Chan K, Shen A, Lima V, Hogg R, Montaner J, Moore D.

HIV Med. 2012 Mar;13(3):141-7. doi: 10.1111/j.1468-1293.2011.00950.x. Epub 2011 Nov 22.

14.

Drug resistance profiles among HIV-1-infected children experiencing delayed switch and 12-month efficacy after using second-line antiretroviral therapy: an observational cohort study in rural China.

Zhao Y, Mu W, Harwell J, Zhou H, Sun X, Cheng Y, Li C, Zhang F.

J Acquir Immune Defic Syndr. 2011 Sep 1;58(1):47-53. doi: 10.1097/QAI.0b013e318229f2a2.

PMID:
21725248
15.

Evolution of resistance mutations during low-level viral replication in HIV-1-infected patients treated with zidovudine/lamivudine/abacavir as a first-line regimen.

Stürmer M, Dauer B, Moesch M, Haberl A, Mueller A, Locher L, Knecht G, Hanke N, Doerr HW, Staszewski S.

Antivir Ther. 2007;12(1):25-30.

PMID:
17503744
16.

Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen.

Cozzi-Lepri A, Phillips AN, Ruiz L, Clotet B, Loveday C, Kjaer J, Mens H, Clumeck N, Viksna L, Antunes F, Machala L, Lundgren JD; EuroSIDA Study Group.

AIDS. 2007 Mar 30;21(6):721-32.

PMID:
17413693
18.

Virologic response to nelfinavir-based regimens: pharmacokinetics and drug resistance mutations (VIRAPHAR study).

Pellegrin I, Breilh D, Montestruc F, Caumont A, Garrigue I, Morlat P, Le Camus C, Saux MC, Fleury HJ, Pellegrin JL.

AIDS. 2002 Jul 5;16(10):1331-40.

PMID:
12131209
19.

HIV-1 drug resistance genotyping from antiretroviral therapy (ART) naïve and first-line treatment failures in Djiboutian patients.

Elmi Abar A, Jlizi A, Darar HY, Kacem MA, Slim A.

Diagn Pathol. 2012 Oct 8;7:138. doi: 10.1186/1746-1596-7-138.

20.

Baseline resistance and virological outcome in patients with virological failure who start a regimen containing abacavir: EuroSIDA study.

Cabrera C, Cozzi-Lepri A, Phillips AN, Loveday C, Kirk O, Ait-Khaled M, Reiss P, Kjaer J, Ledergerber B, Lundgren JD, Clotet B, Ruiz L; EuroSIDA Study Group.

Antivir Ther. 2004 Oct;9(5):787-800.

PMID:
15535417
Items per page

Supplemental Content

Write to the Help Desk